Generic Name and Formulations:
Betamethasone, augmented (as dipropionate) 0.05%; oint; lotion.
Merck & Co., Inc.
Indications for DIPROLENE:
≥13yrs: apply thin film 1–2 times daily; max 50g/week. Lotion: apply a few drops 1–2 times daily; max 50mL/week; max 2 consecutive weeks' treatment per course. Discontinue when control is achieved. Do not occlude.
<13yrs: not recommended.
Avoid use near eyes, on face, groin, or axillae. Do not use for diaper dermatitis or on pre-existing skin atrophy. Risk of HPA axis suppression with high-potency steroids, prolonged use, application to large surface area, use of occlusive dressings, altered skin barrier, liver failure, young age; discontinue gradually, or reduce dose or potency if occurs. Increased risk of posterior subcapsular cataracts and glaucoma; monitor for visual symptoms. Reevaluate periodically. Pregnancy (Cat.C). Nursing mothers.
Erythema, folliculitis, pruritus, vesiculation; contact dermatitis (discontinue if irritation occurs), HPA axis suppression (esp. in children); rare: Cushing's syndrome, hyperglycemia. Also for AF crm: stinging, skin atrophy, telangiectasia, bruising, shininess.
Oint, AF crm—15g, 50g; Lotion—30mL, 60mL
Neurology Advisor Articles
- High-Dose Biotin May Be an Effective Treatment for Progressive MS
- Biobank Data Suggest Vitamin D Reduces Risk for Multiple Sclerosis
- Serious Adverse Events Profile for Cladribine Confirmed With Extended Data
- Patients With Multiple Sclerosis Face Greater Infection Risk
- Ozanimod Reduces Severe Relapses in Multiple Sclerosis More Than Interferon Beta-1a